A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway

NCT06614751 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

112

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Cancers
BRCA Mutation
HRD Cancer
Breast Cancer
Prostate Cancer
Colorectal Cancer
Pancreatic Cancer
Endometrial Cancer
Gastric Cancer
Advanced Cancer
Metastatic Solid Tumors

Interventions

DRUG: DAT-2645 tablet
DRUG: DAT-2645 tablet

Sponsor

Danatlas Pharmaceuticals Co., Ltd